Congress Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Congress Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-70,438	Closed	-$2.82M	–	571
2023 Q1	$2.82M	Hold	70,438	–	–	0.07%	241
2022 Q4	$3.26M	Hold	70,438	–	–	0.08%	218
2022 Q3	$2.92M	Hold	70,438	–	–	0.08%	234
2022 Q2	$4.2M	Hold	70,438	–	–	0.11%	201
2022 Q1	$5.12M	Buy	70,438 +10	+0%	+$696	0.11%	204
2021 Q4	$5.92M	Buy	+70,428	New	+$5.73M	0.12%	199

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Congress Wealth Management's RARE Position: Q2 2023 in Review

Congress Wealth Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2023, closing a stake of 70,438 shares — an estimated $2.82M sold.

Congress Wealth Management first reported a position in RARE in Q4 2021 and held it in 6 quarters. The position peaked at $5.92M in Q4 2021. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2023.

Congress Wealth Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2023 after selling out during the quarter.
Congress Wealth Management sold 70,438 Ultragenyx Pharmaceutical shares in Q2 2023, an estimated $2.82M.
Congress Wealth Management first reported a position in Ultragenyx Pharmaceutical in Q4 2021 and held it in 6 quarters.
Congress Wealth Management's Ultragenyx Pharmaceutical position peaked at $5.92M in Q4 2021.
242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2023.

Based on Congress Wealth Management's 13F filing for Q2 2023, filed 13 Jul 2023.